Australian and New Zealand Committee on Resuscitation. Cardiorespiratory arrest flowcharts. East Melbourne: Australian Resuscitation Council; 2016. https://resus.org.au/guidelines/flowcharts-3/
Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, et al. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia. CNS Drugs 2012;26(3):269–76. https://www.ncbi.nlm.nih.gov/pubmed/22329565
Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012;13(5):450–7. https://www.ncbi.nlm.nih.gov/pubmed/22931174
Dowling J, Isbister GK, Kirkpatrick CM,
Naidoo D, Graudins A. Population pharmacokinetics of intravenous,
intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit
2008;30(4):490-6. https://www.ncbi.nlm.nih.gov/pubmed/18641540
Geib AJ, Babu K, Ewald MB, Boyer EW. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006;118(4):1746–51. https://www.ncbi.nlm.nih.gov/pubmed/17015570
Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol 2016;56(10):1243–53. https://www.ncbi.nlm.nih.gov/pubmed/27145977
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9(1):63–88. https://www.ncbi.nlm.nih.gov/pubmed/29318006
van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006;105(1):51–7. https://www.ncbi.nlm.nih.gov/pubmed/16809994
